Biotech Companies by Disease: Mapping $672B Across 299 Indications

The $672 billion map: 275 biotech companies across 299 diseases

Ask which biotech companies are developing drugs for a given disease and you normally get a list. A list tells you who is in the room. It does not tell you how crowded the room is, how much money is standing in it, or whether the market thinks the room is worth being in at all.

The BiopharmaWatch Disease Map is built to answer the second question. It takes every US-listed drug developer with a market capitalisation between $100 million and $20 billion, reads what each one is actually running clinical trials in, and lays the whole industry out by indication. As of September 4, 2026 that is 275 companies, $672 billion of market value and 299 distinct indications.

The single most useful thing in the dataset is not a ranking. It is a relationship that runs the wrong way round from how most people talk about biotech competition: in this universe, the diseases with the most competitors are the ones where the market pays the least per company. Crowding is priced as a discount, not as validation.

The crowding discount: why competitors make an indication cheaper, not richer

Start with the cleanest comparison in the data.

Achondroplasia has four listed competitors inside the band. The median one is worth $13.8 billion. Non-small cell lung cancer has thirty. The median one is worth $1.1 billion. Same universe, same day, same market cap band at both ends. The market pays roughly 12.5 times more per company to sit in a four-horse race for a rare skeletal dysplasia than it does to be one of thirty names chasing the largest oncology indication in the world.

That is not a quirk of two rows. Bucket all 299 indications by how many competitors they carry and the pattern survives:

From two or three competitors down to ten or more, the median company loses more than half its value: $2.61 billion to $1.17 billion. The honest caveat belongs right here, because the staircase is not perfectly clean. Indications with a single developer sit at $1.71 billion, below the two-to-three bucket rather than above it. A lone developer in a disease nobody else wants is often lonely for a reason. The premium is not paid for solitude, it is paid for scarcity in a race the market believes in, which is a different thing.

Why would this be true? Three mechanisms, none of them exotic. Crowded indications are usually crowded because entry is cheap, which means the entrants are cheap. Second, a thirty-competitor field prices in the odds that any one entrant loses the race, and those odds compound. Third, and most under-discussed, the very largest developers exit the band from the top. Once a company clears $20 billion it leaves this universe by construction, so the fields that produced winners look thinner here than they feel in the news. The map measures who is still competing at small and mid cap scale, not who has already won.

What the crowded fields look like from inside

Non-small cell lung cancer is the extreme case and worth reading in detail. Thirty competitors, thirteen of them still in Phase 1 and twelve in Phase 2, only five in Phase 3. Total market capitalisation competing in the indication is $82.3 billion, the largest figure on the map, and yet allocated capital, which splits each company's value evenly across the indications it runs in, is only $16.2 billion. The gap between those two numbers is the tell: almost nobody in lung cancer is only in lung cancer. Three of the thirty are pure plays.

Duchenne muscular dystrophy is the same structure in miniature and a better warning, because DMD is not a large indication by patient count. Thirteen competitors, a median market cap of $607 million, and five pure plays whose entire equity story rests on one disease. When a field like that gets a negative readout, there is no second programme to fall back on.

Four competitive structures, and which one holds the money

Cross two folds, the number of competitors (six or more counts as crowded) and whether the median competitor is worth more than the universe median of $1.20 billion, and every contested indication lands in one of four quadrants.

The distribution is the finding. Concentrated bet is by far the largest pool of capital: 52 indications holding $232 billion, more than gold rush and knife fight combined. The market's money is overwhelmingly in small fields with large companies in them, not in the crowded races that dominate conference agendas.

Knife fight is the quadrant to know by name. Twelve indications, $68 billion, and nine of the twelve are oncology: lung, acute myeloid leukaemia, colorectal, gastric, glioblastoma, prostate, breast, pancreatic and non-Hodgkin's lymphoma. If you screen for clinical stage biotech competitors by indication and keep landing in the same nine tumour types, you are not finding an edge, you are finding the part of the market where everyone else already is.

Breast cancer makes the point uncomfortably well. Ten competitors inside the band and a median market cap of $288 million, among the cheapest cohorts on the whole map. One of the most common cancers in the world, and the listed small and mid cap field chasing it is a collection of microcaps.

The biggest indications by allocated capital

Allocated capital is the honest denominator for a question like this. It divides each company's market capitalisation evenly across the indications it runs clinical programmes in, so a seven-indication company contributes a seventh of itself to each, and every dollar of the $672 billion is counted exactly once. Ranked that way, here is where the industry's money actually sits.

Three observations that a headline count of competitors would never surface.

• The top ten indications hold 22.3% of all the capital, the top twenty hold 35.8%, and the top fifty hold 60.3%. Three fifths of the industry's value is in a sixth of its diseases.
• MASH ranks second at $19.4 billion with only four competitors, and one of them, Madrigal, is $12.5 billion of the $37.9 billion competing there. Take Madrigal out and MASH is a normal mid cap field.
• Obesity, the most talked-about indication in the sector, ranks sixth at $13.1 billion with a median company of $2.4 billion. Six of its nine listed competitors are still in Phase 1. The listed small and mid cap obesity trade is an early-stage trade, whatever the coverage suggests.

Atopic dermatitis takes the top spot at $20.4 billion across eleven competitors, with ten dated catalysts in the next twelve months. It is the rare indication that is both genuinely crowded and genuinely well funded, which is what the gold rush label is for.

Most diseases are not races at all

Here is the number that reframes the whole exercise. Of 299 indications, 198 have exactly one listed developer in the band. Only 101 are contested by two or more. The median indication on this map is not a race, it is one company.

Those 198 single-developer indications hold $182 billion, about 27% of the universe, while the 101 contested ones hold $490 billion. So competition concentrates capital, as you would expect. But the sheer count matters for anyone screening: two thirds of the disease space has no competitive dynamic to analyse at all, and 108 of the 275 companies are pure plays running clinical programmes in a single indication.

Infectious disease is the starkest example. Thirteen indications, $16.5 billion, ten companies, and zero contested indications. Not one infectious disease indication in this universe has two listed small or mid cap developers competing in it. Whatever the pandemic did to the sector's ambitions, the listed field has emptied out.

Winner takes most: one company is over half of 64 contested fields

Calling an indication contested is not the same as calling it competitive. In 64 of the 101 contested indications, a single company accounts for more than half the market capitalisation competing there. In 21 of them, one company is more than three quarters of the field. What looks like a race is often one large company and a queue of much smaller ones.

Breast cancer again: ten competitors, and the largest holds 81.2% of the $19.8 billion competing. Duchenne: thirteen competitors, top company 44.6%. Atopic dermatitis, at 27.2%, is one of the genuinely flat fields, which is part of why it prices well.

The most instructive case is Alzheimer's disease. Five competitors inside the band, none in Phase 3, four of the five in Phase 1, and a median market cap of $397 million. Total capital allocated to Alzheimer's from this universe is $2.9 billion, less than a quarter of what sits in MASH. The largest company competing there holds 73.6% of the field's market cap on the strength of a Phase 1 programme, because it happens to be a $12.2 billion RNAi company that runs six other things. Read the top company share without reading the phase and you will badly misjudge that indication.

Capital by therapeutic area

Rolled up to therapeutic area, the biotech pipeline by therapeutic area looks like this.

Oncology is the biggest by capital at $187 billion, but the more interesting column is the ratio of contested to total. Oncology spreads $187 billion across 119 indications and only 34 of them are contested. Its reputation for crowding comes from a handful of famous tumour types; the long tail of oncology is as thin as anywhere else on the map.

Immunology and inflammation is the opposite shape: $139 billion across 51 indications with 23 contested, worked by 82 companies. It is the densest large area in the universe, which is exactly what you would expect from a field where one validated mechanism gets pursued into eight adjacent diseases.

Ophthalmology is the quiet outlier. Nine indications, six of them contested, the highest contested rate on the map, on just $17 billion of capital and 13 companies. Small area, unusually competitive inside it.

How to use this when you are screening

A few practical readings, offered as observations rather than recommendations.

• Read competitor count and median market cap together, never separately. Thirty competitors at a $1.1 billion median and four at a $13.8 billion median are opposite situations, and the count alone hides that completely.
• Check the top company share before calling a field competitive. Two thirds of contested indications are majority-held by one name.
• Check the phase mix before reading a valuation. Across the map, 681 company-indication programmes break down as 200 in Phase 3, 257 in Phase 2 and 224 in Phase 1. An indication can look richly capitalised while every programme in it is years from data.
• Pure plays are the leverage and the risk. 108 of the 275 companies run in exactly one indication. They are how you get concentrated exposure to a thesis, and they are why a single readout can halve a field.
• Timing is dense. 257 of the 299 indications carry at least one dated catalyst in the next twelve months, so most fields on this map reprice inside a year.

How the map is built

Universe: US-listed drug developers with a market capitalisation between $100 million and $20 billion, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.

An asset attributed to three or more different companies is treated as shared standard of care rather than any one company's programme, and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data, so without this gate every tumour type would show a phantom field. A programme counts only where at least one industry-sponsored trial supports it, which keeps investigator-initiated academic studies of third-party drugs out of the competitor counts.

Allocated capital divides each company's market capitalisation evenly across the indications it runs clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe; the two columns answer different questions and should not be compared to each other. Approved incumbents are excluded from competitor counts, and companies above $20 billion are outside the universe by construction, so a field that has already produced a large winner will read thinner here than it feels. Third-party market size estimates are not used anywhere on this page. All figures as of September 4, 2026.

Explore the map

The full biotech disease map is free and interactive: filter 299 indications by therapeutic area, competitive structure, competitor count or capital, and open any indication for the complete competitor list with drug, phase, trial count, market cap and next dated catalyst. Every indication has its own page, so "which companies are developing drugs for X" is one click rather than an afternoon.

Download the full Disease Map report as a PDF (free, no signup).

Related tools: the biotech screener for company-level filtering, the FDA calendar for the regulatory dates behind these programmes, and the clinical trial monitor for the underlying study records.

This material is for information only and is not investment advice or a recommendation to buy or sell any security. Market capitalisations and competitive structures change; the map is rebuilt from current filings and trial records rather than frozen.